Related pages Drug Information Summaries Approval Process for New Cancer Treatments Access to Investigational Drugs: Q & A

This page contains brief information about alemtuzumab and a collection of links to more information from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA).

US Brand Name(s):		Campath
FDA Approved:		Yes

Alemtuzumab is approved by the U. S. Food and Drug Administration (FDA) to treat patients with B-cell chronic lymphocytic leukemia (B-CLL).

Alemtuzumab is also being studied in other types of cancer and other conditions.

Patient Information Sheet on Alemtuzumab - A lay language summary of important information about this drug that may include the following:

• FDA warnings or alerts about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This FDA patient information sheet applies only to approved uses of the medicine. However, much of the information may also apply to unapproved uses that are being studied.

FDA Approval for Alemtuzumab - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

The Making of a Monoclonal Antibody (06/13/2006) - Information about the use of this drug to treat cancer.

Clinical Trials for Alemtuzumab - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Back to Top